2026-03-27 20:40:42
Stoke Therapeutics Dismisses KPMG, Appoints Ernst & Young as New Auditor
Expected Stock impact: None Expected
On March 23, 2026, Stoke Therapeutics, Inc. announced the dismissal of KPMG LLP as its independent registered public accounting firm. The decision was made by the Audit Committee of the Board of Directors. KPMG's reports on the consolidated financial statements for the fiscal years ended December 31, 2025, and 2024, did not contain any adverse opinions or disclaimers. Furthermore, there were no disagreements between KPMG and the company regarding accounting principles or practices during their tenure. Following the dismissal, the Audit Committee approved the engagement of Ernst & Young LLP as the new independent registered public accounting firm for the fiscal year ending December 31, 2026. This transition is expected to maintain the integrity of the company's financial reporting and auditing processes. The company has provided KPMG with a copy of the disclosures made in this Current Report on Form 8-K and has requested a letter from KPMG addressing their agreement with the statements made. A copy of KPMG's letter, dated March 27, 2026, is included as an exhibit to this report. The change in auditors is a routine administrative matter and is not expected to have a significant impact on the company's operations or financial position.
